Back to resultsStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
Primary Purpose
Endometrial Neoplasms
Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
pembrolizumab
carboplatin
paclitaxel
docetaxel
cisplatin
Sponsored by
About this trial
This is an interventional treatment trial for Endometrial Neoplasms focused on measuring Programmed Cell Death-1 (PD1, PD-1), Programmed Cell Death 1 Ligand 1 (PDL1, PD-L1), Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
Eligibility Criteria
The main inclusion and exclusion criteria include but are not limited to the following:
Inclusion Criteria:
- Has a histologically confirmed diagnosis of inoperable, Stage III or IV or recurrent Endometrial Carcinoma (EC) or carcinosarcoma (mixed Mullerian tumor) that is centrally confirmed as dMMR
Has received no prior systemic therapy for EC except for the following:
- May have received prior radiation with or without radiosensitizing chemotherapy if >2 weeks before the start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system (CNS) disease
- May have received prior hormonal therapy for treatment of EC, provided that it was discontinued ≥1 week prior to randomization
- Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before randomization.
- Is not pregnant or breastfeeding and agrees to not donate eggs and use a highly effective contraceptive method for 120 days after the last dose of pembrolizumab or 180 days after the last dose of chemotherapy if a woman of childbearing potential (WOCBP)
- Has a negative highly sensitive pregnancy test (urine or serum) within 24 hours for urine or 72 hours for serum before the first dose of study intervention if a WOCBP
- Provides an archival tumor tissue sample or newly obtained (core, incisional, or excisional) biopsy of a tumor lesion not previously irradiated for verification of dMMR status and histology
- Is Hepatitis B surface antigen (HBsAg) positive but has received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and has undetectable HBV viral load prior to randomization
- Has a history of Hepatitis C virus (HCV) infection but has undetectable HCV viral load at screening.
Exclusion Criteria:
- Has uterine mesenchymal tumor such as an endometrial stromal sarcoma, leiomyosarcoma, or other types of pure sarcomas. Adenosarcomas and neuroendocrine tumors are not allowed
- Has EC of any histology that is proficient mismatch repair (pMMR)
- Is a candidate for curative-intent surgery or curative-intent radiotherapy
- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], Tumor necrosis factor receptor superfamily, member 4 [OX 40], tumor necrosis factor receptor superfamily member 9 [CD137])
- Has received prior systemic anticancer therapy including investigational agents for EC. This includes any chemotherapy given for EC other than as a radiosensitizer
- Has had a major operation and has not recovered adequately from the procedure and/or any complications from the operation before starting study intervention
- Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed
- Is currently participating in or has participated in a study of an investigational agent for EC, has participated in a study of an investigational agent for non-EC within 4 weeks before the first dose of study intervention, or has used an investigational device within 4 weeks before the first dose of study intervention
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (excluding carcinoma in situ of the bladder) that have undergone potentially curative therapy are not excluded
- Has known active CNS metastases and/or carcinomatous meningitis
- Has a known intolerance to any study intervention and/or any of its excipients
- Has an active autoimmune disease that has required systemic treatment in past 2 years
- Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- Has an active infection, requiring systemic therapy
- Has a known history of human immunodeficiency virus (HIV) infection
- Has had an allogenic tissue/solid organ transplant
Sites / Locations
- HonorHealth-USOR HonorHealth ( Site 8000)Recruiting
- Moores Cancer Center ( Site 0037)Recruiting
- Kaiser Permanente Riverside Medical Center ( Site 0045)
- Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0013)Recruiting
- Mount Sinai Cancer Center ( Site 0018)
- Sarasota Memorial Hospital ( Site 0005)
- Northside Hospital ( Site 0017)
- Southeastern Regional Medical Center ( Site 0046)
- Midwestern Regional Medical Center,Inc. DBA CTCA, Chicago ( Site 0003)
- St. Vincent Hospital and Health Care Center, Inc ( Site 0006)
- Baptist Health Lexington ( Site 0042)Recruiting
- Maryland Oncology Hematology, P.A.-USOR Maryland Oncology Hematology, P.A. ( Site 8002)Recruiting
- University of Massachusetts Medical School-Division of Gynecologic Oncology ( Site 0008)Recruiting
- Karmanos Cancer Institute ( Site 0029)
- St. Dominic's Hospital ( Site 0024)
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0026)
- The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0023)
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0016)Recruiting
- Icahn School of Medicine at Mount Sinai ( Site 0052)
- Memorial Sloan Kettering Cancer Center ( Site 0009)
- FirstHealth Clinical Trials ( Site 0050)Recruiting
- Sanford Medical Center ( Site 0054)
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0055)
- University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0039)Recruiting
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C
- Providence Portland Medical Center ( Site 0031)
- Sidney Kimmel Cancer Center - Jefferson Health ( Site 0053)Recruiting
- University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0034)
- AHN West Penn Hospital ( Site 0011)
- Asplundh Cancer Pavilion ( Site 0014)Recruiting
- Sanford Cancer Center-Gynecologic Oncology ( Site 0002)
- Texas Oncology - Austin-USOR Texas Oncology - Austin ( Site 8003)Recruiting
- Texas Oncology - Dallas-USOR Texas Oncology - Dallas (Sammons) ( Site 8005)Recruiting
- Lyndon B. Johnson General Hospital ( Site 0056)
- University of Texas MD Anderson Cancer Center ( Site 0040)
- Texas Oncology - Tyler-USOR Texas Oncology - Northeast Texas ( Site 8004)Recruiting
- VCU Health Adult Outpatient Pavillion ( Site 0022)Recruiting
- Northern Cancer Institute ( Site 0206)Recruiting
- Westmead Hospital-Department of Gynaecological Oncology ( Site 0201)
- Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( SiRecruiting
- Monash Health ( Site 0202)Recruiting
- Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0207)Recruiting
- Epworth Freemasons ( Site 0203)Recruiting
- St. John of God Subiaco Hospital-Oncology Clinical Trials Unit ( Site 0204)Recruiting
- Institut Jules Bordet-Medicine Oncology ( Site 0321)Recruiting
- Grand Hôpital de Charleroi-Oncology & Hematology ( Site 0323)Recruiting
- Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman ( Site 0320)Recruiting
- Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 3005)Recruiting
- ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 3001)Recruiting
- A. C. Camargo Cancer Center-CAPEC ( Site 3003)Recruiting
- Cross Cancer Institute ( Site 0513)Recruiting
- BC Cancer Kelowna ( Site 0517)Recruiting
- BC Cancer Vancouver-Clinical Trials Unit ( Site 0518)Recruiting
- Sunnybrook Health Sciences - Odette Cancer Centre ( Site 0509)Recruiting
- Princess Margaret Cancer Centre ( Site 0510)Recruiting
- Jewish General Hospital ( Site 0504)Recruiting
- Centre Hospitalier de l'Université de Montréal ( Site 0519)Recruiting
- McGill University Health Centre ( Site 0505)Recruiting
- Saskatoon Cancer Center-Clinical Research Department ( Site 0520)Recruiting
- FALP-UIDO ( Site 0602)Recruiting
- Pontificia Universidad Catolica de Chile-Centro del Cáncer ( Site 0604)Recruiting
- Bradfordhill-Clinical Area ( Site 0603)Recruiting
- Anhui Provincial Hospital-Obstetrics and Gynecology ( Site 0730)Recruiting
- Beijing Obstetric and Gynecology Hospital ( Site 0740)Recruiting
- Peking University First Hospital ( Site 0723)Recruiting
- Beijing Cancer hospital ( Site 0715)Recruiting
- 2nd Affiliated Hospital Chongqing Medical Universi ( Site 0745)Recruiting
- Southwest Hospital of Third Military Medical University ( Site 0719)Recruiting
- Fuling Central Hospital ( Site 0733)Recruiting
- Fujian Provincial Cancer Hospital ( Site 0720)Recruiting
- SUN YAT-SEN UNIVERSITY CANCER CENTRE ( Site 0710)Recruiting
- Cancer Hospital of Shantou University Medical College ( Site 0732)Recruiting
- Affiliated Hospital of Guangdong Medical College ( Site 0731)Recruiting
- Guangxi Medical University Affiliated Tumor Hospital-Gynecological oncology ( Site 0704)Recruiting
- Hainan General Hospital ( Site 0703)Recruiting
- Harbin Medical University Cancer Hospital ( Site 0711)Recruiting
- Henan Cancer Hospital ( Site 0713)Recruiting
- Wuhan Union Hospital-Medical Oncology ( Site 0716)Recruiting
- Xiangya Hospital Central South University-Gynecology ( Site 0708)Recruiting
- Hunan Cancer Hospital ( Site 0709)Recruiting
- Jiangsu Province Hospital-Oncology Department ( Site 0707)Recruiting
- The First Affiliated Hospital of Nanchang University ( Site 0729)Recruiting
- The First Hospital of Jilin University ( Site 0705)Recruiting
- Shaanxi Provincial Cancer Hospital ( Site 0714)Recruiting
- Binzhou Medical University Hospital-Oncology department ( Site 0735)Recruiting
- Obstetrics & Gynecology Hospital of Fudan University ( Site 0702)Recruiting
- Shanghai First Maternity and Infant Hospital-Gynecology department ( Site 0717)Recruiting
- West China Second University Hospital Sichuan University ( Site 0701)Recruiting
- Tianjin Medical University Cancer Institute and Hospital ( Site 0706)Recruiting
- Yunnan Province Cancer Hospital-Gynecology Department ( Site 0721)Recruiting
- The Affiliated Women's Hospital of Zhejiang University-Obstetrics and Gynecology ( Site 0726)Recruiting
- Zhejiang Cancer Hospital-Oncology ( Site 0700)Recruiting
- The First Affiliated Hospital of Wenzhou Medical University-Gynecology ( Site 0725)Recruiting
- Fakultní nemocnice Brno Bohunice-Gynekologicko-porodnicka klinika ( Site 0404)Recruiting
- Fakultni nemocnice Ostrava-Gynekologicko-porodnicka klinika ( Site 0403)Recruiting
- Nemocnice AGEL Novy Jicin a.s.-Oddeleni radioterapie a onkologie ( Site 0406)Recruiting
- Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 0402)Recruiting
- Vseobecna fakultni nemocnice v Praze-Gynekologicko-porodnicka klinika 1.LF a VFN ( Site 0405)Recruiting
- Fakultni nemocnice Bulovka-Gynekologicko-porodnicka klinika ( Site 0401)Recruiting
- Nemocnice Tomase Bati ve Zline-Onkologické oddělení ( Site 0407)Recruiting
- Fakultni nemocnice Kralovske Vinohrady-Gynekologicko-porodnická klinika ( Site 0408)Recruiting
- Rigshospitalet ( Site 0903)Recruiting
- Herlev and Gentofte Hospital ( Site 0902)Recruiting
- Aalborg Universitetshospital, Syd ( Site 0905)Recruiting
- Roskilde Sygehus-Oncology department ( Site 0904)Recruiting
- Tampereen yliopistollinen sairaala-Gynecology and Obstetrics ( Site 1001)Recruiting
- Kuopion Yliopistollinen Sairaala ( Site 1002)Recruiting
- Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus) ( Site 1003)Recruiting
- Universitaetsklinikum Ulm ( Site 1106)Recruiting
- Universitätsklinikum Bonn-Gynaecological oncology ( Site 1105)Recruiting
- Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Frauenheilkunde und GeburRecruiting
- Charité Campus Virchow-Klinikum ( Site 1103)Recruiting
- Országos Onkológiai Intézet-Ngyógyászat ( Site 1201)Recruiting
- Bon Secours Cork Hospital ( Site 1305)Recruiting
- St. James's Hospital-Cancer clinical trials office ( Site 1301)Recruiting
- Soroka Medical Center ( Site 1403)Recruiting
- Rambam Health Care Campus-Gyneco-oncology unit ( Site 1402)Recruiting
- Edith Wolfson Medical Center-Obstetrics & Gynecology ( Site 1405)Recruiting
- Shaare Zedek Medical Center ( Site 1404)Recruiting
- Sheba Medical Center ( Site 1401)Recruiting
- Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Oncologia Sperimentale Uro-Genitale ( Site 1Recruiting
- IRCCS - AOU di Bologna-SSD Oncologia medica Addarii ( Site 1503)Recruiting
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-Oncologia Medica ( Site 1513)Recruiting
- Fondazione Policlinico Universitario Agostino Gemelli-Ginecologia Oncologica ( Site 1502)Recruiting
- Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Chirurgia Ginecologica ( Site 150Recruiting
- Ospedale Mauriziano-SCDU ONCOLOGIA MEDICA ( Site 1514)Recruiting
- Istituto Nazionale Tumori Regina Elena-Oncologia Medica 1 ( Site 1504)Recruiting
- Azienda Ospedaliera Universitaria Careggi-SOD ONCOLOGIA MEDICA ( Site 1509)Recruiting
- AULSS8 Berica-Ospedale S.Bortolo-ONCOLOGIA CLINICA ( Site 1510)Recruiting
- Istituto Europeo di Oncologia IRCCS-Divisione di Ginecologia Oncologica ( Site 1506)Recruiting
- National Cancer Center Hospital East ( Site 1604)Recruiting
- National Hospital Organization Shikoku Cancer Center ( Site 1611)Recruiting
- Ehime University Hospital ( Site 1614)Recruiting
- Kurume University Hospital ( Site 1612)Recruiting
- Gunma Prefectural Cancer Center-Gynecology ( Site 1603)Recruiting
- Hokkaido University Hospital ( Site 1601)Recruiting
- Tsukuba University Hospital ( Site 1618)Recruiting
- Iwate Medical University Hospital ( Site 1602)Recruiting
- Niigata University Medical & Dental Hospital ( Site 1613)Recruiting
- Saitama Medical University International Medical Center ( Site 1605)Recruiting
- Shizuoka Cancer Center ( Site 1609)Recruiting
- National Cancer Center Hospital ( Site 1607)Recruiting
- Japanese Foundation for Cancer Research ( Site 1616)Recruiting
- The Jikei University Hospital ( Site 1615)Recruiting
- Keio university hospital ( Site 1606)Recruiting
- National Hospital Organization Kyushu Cancer Center ( Site 1608)Recruiting
- Osaka International Cancer Institute ( Site 1617)Recruiting
- Seoul National University Hospital ( Site 2302)Recruiting
- Severance Hospital, Yonsei University Health System-Gynecologic cancer center ( Site 2301)Recruiting
- Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology ( Site 2303)Recruiting
- Gangnam Severance Hospital ( Site 2304)Recruiting
- Radboudumc-Medical Oncology ( Site 1703)Recruiting
- Maastricht UMC+ ( Site 1709)Recruiting
- Catharina Ziekenhuis-Oncology ( Site 1704)Recruiting
- Amsterdam UMC, locatie AMC ( Site 1706)Recruiting
- Leids Universitair Medisch Centrum-Medical Oncology ( Site 1702)Recruiting
- Erasmus Medisch Centrum-Medical Oncology ( Site 1701)Recruiting
- University Medical Center Groningen ( Site 1707)Recruiting
- Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 1705)Recruiting
- Auckland City Hospital-Cancer & Blood Research ( Site 1801)Recruiting
- Oslo universitetssykehus, Radiumhospitalet ( Site 1901)Recruiting
- Centrum Onkologii Ziemi Lubelskiej ( Site 2006)Recruiting
- Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 2007)Recruiting
- Szpital Kliniczny im. Księżnej Anny Mazowieckiej ( Site 2009)Recruiting
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Ginekologii Onkologicznej ( SitRecruiting
- Bialostockie Centrum Onkologii-Oddzial Onkologii Ginekologicznej ( Site 2003)Recruiting
- Narodowy Instytut Onkologii - Oddzial w Gliwicach-III Klinika Radioterapii i Chemioterapii ( Site 20Recruiting
- Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 2010)Recruiting
- Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Me-Oddzial Ginekologii Onkologicznej ( SitRecruiting
- Moscow City Oncology Hospital #62 ( Site 2204)
- Yaroslavl Regional Cancer Hospital-Oncology ( Site 2202)
- Institut Català d'Oncologia - L'Hospitalet-Medical Oncology ( Site 2406)Recruiting
- CHUAC-Complejo Hospitalario Universitario A Coruña ( Site 2405)Recruiting
- Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 2402)Recruiting
- COMPLEJO HOSPITALARIO DE NAVARRA ( Site 2407)Recruiting
- Fundación Instituto Valenciano de Oncología-Oncologico ( Site 2404)Recruiting
- Hospital Universitari Vall d'Hebron ( Site 2403)Recruiting
- HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 2401)Recruiting
- Skånes Universitetssjukhus Lund-Department of Hematology ( Site 2504)Recruiting
- Karolinska Universitetssjukhuset Solna ( Site 2502)Recruiting
- Norrlands universitetssjukhus-Cancercentrum ( Site 2503)Recruiting
- Taichung Veterans General Hospital ( Site 2602)Recruiting
- NATIONAL CHENG-KUNG UNI. HOSP. ( Site 2604)Recruiting
- National Taiwan University Hospital ( Site 2603)Recruiting
- Mackay Memorial Hospital ( Site 2601)Recruiting
- Taipei Veterans General Hospital ( Site 2605)Recruiting
- Istanbul Universitesi Cerrahpasa ( Site 2702)Recruiting
- Hacettepe Universite Hastaneleri-oncology hospital ( Site 2704)Recruiting
- Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 2706)Recruiting
- Akdeniz Universitesi Hastanesi ( Site 2701)Recruiting
- Istanbul University Capa Campus-department of obstetrics and gynaecology ( Site 2705)Recruiting
- T.C. Saglik Bakanligi Turkiye Kamu Hastaneleri Kurumu - Bakirkoy Dr. Sadi Konuk Egitim ve ArastirmaRecruiting
- St Bartholomew's Hospital ( Site 2804)Recruiting
- The Christie ( Site 2807)Recruiting
- The Beatson West of Scotland Cancer Centre ( Site 2805)
- ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 2806)Recruiting
- Hammersmith Hospital-Medical Oncology ( Site 2808)Recruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Pembrolizumab
Carboplatin+paclitaxel
Arm Description
Participants receive pembrolizumab 400 mg via IV infusion on Day 1 of each 6-week cycle (Q6W) for up to 18 cycles (up to approximately 2 years).
Participants receive a combination of paclitaxel 175 mg/m^2 on Day 1 of each 3-week cycle (Q3W) and carboplatin AUC 5 or 6 on Day 1 Q3W for 6 cycles (up to approximately 4 months). Participants who experience a severe hypersensitivity reaction to paclitaxel or an adverse event (AE) requiring discontinuation of paclitaxel may receive docetaxel 75 mg/m^2 in place of paclitaxel on Day 1 Q3W after Sponsor consultation. Participants who experience a severe hypersensitivity reaction to carboplatin or an AE requiring discontinuation of carboplatin may receive cisplatin 75 mg/m^2 in place of carboplatin on Day 1 Q3W after Sponsor consultation.
Outcomes
Primary Outcome Measures
Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
PFS is defined as the time from randomization to the first documented disease progression (PD) per RECIST 1.1 or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by BICR will be reported for participants.
Overall Survival
OS is defined as the time from randomization to death due to any cause. The OS will be reported for all participants.
Secondary Outcome Measures
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
ORR is defined as the percentage of participants who have a best response of confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience CR or PR as assessed by BICR will be presented.
Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
DCR is defined, per RECIST 1.1, as the percentage of participants who have achieved Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) or demonstrated Stable Disease (SD) for at least 24 weeks. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD.) The DCR as assessed by BICR will be presented.
Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
DOR is defined as the time from first documented evidence of CR or PR until the first documented date of disease progression (PD) or death due to any cause, whichever occurs first, for participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented.
Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Investigator
PFS is defined as the time from randomization to the first documented disease progression (PD) per RECIST 1.1 or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by investigator will be reported for participants.
Progression-Free Survival 2 (PFS2) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Investigator
PFS2 is defined as the time from randomization to subsequent disease progression (PD) per RECIST 1.1 after initiation of a new anticancer therapy, or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS2 per RECIST 1.1 as assessed by investigator will be reported for participants.
Number of Participants Who Experience at Least One Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experience an AE will be reported.
Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinue study treatment due to an AE will be reported.
Change From Baseline in European Organization for Research And Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (GHS) (Item 29) And Quality of Life (QoL) (Item 30) Combined Score
The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score will be presented.
Change From Baseline in European Organization for Research And Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Physical Functioning (Items 1-5) Combined Score
The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) score will be presented. A higher score indicates a better quality of life.
Full Information
NCT ID
NCT05173987
First Posted
December 20, 2021
Last Updated
October 18, 2023
Sponsor
Merck Sharp & Dohme LLC
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
1. Study Identification
Unique Protocol Identification Number
NCT05173987
Brief Title
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
Official Title
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 3, 2022 (Actual)
Primary Completion Date
July 17, 2026 (Anticipated)
Study Completion Date
July 17, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Merck Sharp & Dohme LLC
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma who have not previously been treated with prior systemic chemotherapy.
The primary study hypotheses are that pembrolizumab is superior to the combination of carboplatin and paclitaxel with respect to Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and Overall Survival (OS).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endometrial Neoplasms
Keywords
Programmed Cell Death-1 (PD1, PD-1), Programmed Cell Death 1 Ligand 1 (PDL1, PD-L1), Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
280 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Pembrolizumab
Arm Type
Experimental
Arm Description
Participants receive pembrolizumab 400 mg via IV infusion on Day 1 of each 6-week cycle (Q6W) for up to 18 cycles (up to approximately 2 years).
Arm Title
Carboplatin+paclitaxel
Arm Type
Active Comparator
Arm Description
Participants receive a combination of paclitaxel 175 mg/m^2 on Day 1 of each 3-week cycle (Q3W) and carboplatin AUC 5 or 6 on Day 1 Q3W for 6 cycles (up to approximately 4 months). Participants who experience a severe hypersensitivity reaction to paclitaxel or an adverse event (AE) requiring discontinuation of paclitaxel may receive docetaxel 75 mg/m^2 in place of paclitaxel on Day 1 Q3W after Sponsor consultation. Participants who experience a severe hypersensitivity reaction to carboplatin or an AE requiring discontinuation of carboplatin may receive cisplatin 75 mg/m^2 in place of carboplatin on Day 1 Q3W after Sponsor consultation.
Intervention Type
Biological
Intervention Name(s)
pembrolizumab
Other Intervention Name(s)
KEYTRUDA®, MK-3475
Intervention Description
Intravenous (IV) infusion
Intervention Type
Drug
Intervention Name(s)
carboplatin
Other Intervention Name(s)
PARAPLATIN®
Intervention Description
IV infusion
Intervention Type
Drug
Intervention Name(s)
paclitaxel
Other Intervention Name(s)
TAXOL®
Intervention Description
IV infusion
Intervention Type
Drug
Intervention Name(s)
docetaxel
Other Intervention Name(s)
TAXOTERE®
Intervention Description
IV infusion
Intervention Type
Drug
Intervention Name(s)
cisplatin
Other Intervention Name(s)
PLATINOL-AQ®
Intervention Description
IV infusion
Primary Outcome Measure Information:
Title
Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Description
PFS is defined as the time from randomization to the first documented disease progression (PD) per RECIST 1.1 or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by BICR will be reported for participants.
Time Frame
Up to approximately 30 months
Title
Overall Survival
Description
OS is defined as the time from randomization to death due to any cause. The OS will be reported for all participants.
Time Frame
Up to approximately 49 months
Secondary Outcome Measure Information:
Title
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Description
ORR is defined as the percentage of participants who have a best response of confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience CR or PR as assessed by BICR will be presented.
Time Frame
Up to approximately 30 months
Title
Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Description
DCR is defined, per RECIST 1.1, as the percentage of participants who have achieved Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) or demonstrated Stable Disease (SD) for at least 24 weeks. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD.) The DCR as assessed by BICR will be presented.
Time Frame
Up to approximately 30 months
Title
Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Description
DOR is defined as the time from first documented evidence of CR or PR until the first documented date of disease progression (PD) or death due to any cause, whichever occurs first, for participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented.
Time Frame
Up to approximately 30 months
Title
Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Investigator
Description
PFS is defined as the time from randomization to the first documented disease progression (PD) per RECIST 1.1 or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by investigator will be reported for participants.
Time Frame
Up to approximately 30 months
Title
Progression-Free Survival 2 (PFS2) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Investigator
Description
PFS2 is defined as the time from randomization to subsequent disease progression (PD) per RECIST 1.1 after initiation of a new anticancer therapy, or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS2 per RECIST 1.1 as assessed by investigator will be reported for participants.
Time Frame
Up to approximately 30 months
Title
Number of Participants Who Experience at Least One Adverse Event (AE)
Description
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experience an AE will be reported.
Time Frame
Up to approximately 27 months
Title
Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)
Description
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinue study treatment due to an AE will be reported.
Time Frame
Up to approximately 24 months
Title
Change From Baseline in European Organization for Research And Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (GHS) (Item 29) And Quality of Life (QoL) (Item 30) Combined Score
Description
The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score will be presented.
Time Frame
Baseline and up to approximately 25 months
Title
Change From Baseline in European Organization for Research And Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Physical Functioning (Items 1-5) Combined Score
Description
The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) score will be presented. A higher score indicates a better quality of life.
Time Frame
Baseline and up to approximately 25 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
The main inclusion and exclusion criteria include but are not limited to the following:
Inclusion Criteria:
Has a histologically confirmed diagnosis of inoperable, Stage III or IV or recurrent Endometrial Carcinoma (EC) or carcinosarcoma (mixed Mullerian tumor) that is centrally confirmed as dMMR.
Has radiographically evaluable disease, either measurable or non-measurable per RECIST 1.1, as assessed by the investigator. Note: primary Stage IVB that has undergone surgical resection is allowed regardless of presence of measurable or evaluable disease.
Has received no prior systemic therapy for EC except for the following:
May have received 1 prior line of systemic platinum-based adjuvant and/or neoadjuvant chemotherapy in the setting of curative-intent resection if the recurrence occurred ≥6 months after the last dose of chemotherapy.
May have received prior radiation with or without radiosensitizing chemotherapy if >2 weeks before the start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system (CNS) disease.
May have received prior hormonal therapy for treatment of EC, provided that it was discontinued ≥1 week prior to randomization.
Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before randomization.
Is not pregnant or breastfeeding and agrees to not donate eggs and use a highly effective contraceptive method for 120 days after the last dose of pembrolizumab or 180 days after the last dose of chemotherapy if a woman of childbearing potential (WOCBP).
Has a negative highly sensitive pregnancy test (urine or serum) within 24 hours for urine or 72 hours for serum before the first dose of study intervention if a WOCBP.
Provides an archival tumor tissue sample or newly obtained (core, incisional, or excisional) biopsy of a tumor lesion not previously irradiated for verification of dMMR status and histology.
Is Hepatitis B surface antigen (HBsAg) positive but has received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and has undetectable HBV viral load prior to randomization.
Has a history of Hepatitis C virus (HCV) infection but has undetectable HCV viral load at screening.
Exclusion Criteria:
Has uterine mesenchymal tumor such as an endometrial stromal sarcoma, leiomyosarcoma, or other types of pure sarcomas. Adenosarcomas and neuroendocrine tumors are not allowed.
Has EC of any histology that is proficient mismatch repair (pMMR).
Is a candidate for curative-intent surgery or curative-intent radiotherapy.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], Tumor necrosis factor receptor superfamily, member 4 [OX 40], tumor necrosis factor receptor superfamily member 9 [CD137]).
Has received prior systemic anticancer therapy including investigational agents for any advanced or metastatic EC. (Note: Prior chemotherapy administered as adjuvant therapy, neoadjuvant therapy, and/or concurrently with radiation is permitted.
Has had a major operation and has not recovered adequately from the procedure and/or any complications from the operation before starting study intervention.
Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.
Is currently participating in or has participated in a study of an investigational agent for EC, has participated in a study of an investigational agent for non-EC within 4 weeks before the first dose of study intervention, or has used an investigational device within 4 weeks before the first dose of study intervention.
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.
Has a known additional malignancy that is progressing or has required active treatment within the past 3 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (excluding carcinoma in situ of the bladder) that have undergone potentially curative therapy are not excluded.
Has known active CNS metastases and/or carcinomatous meningitis.
Has a known intolerance to any study intervention and/or any of its excipients.
Has an active autoimmune disease that has required systemic treatment in past 2 years.
Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
Has an active infection, requiring systemic therapy.
Has a known history of human immunodeficiency virus (HIV) infection.
Has had an allogenic tissue/solid organ transplant.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Toll Free Number
Phone
1-888-577-8839
Email
Trialsites@merck.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Director
Organizational Affiliation
Merck Sharp & Dohme LLC
Official's Role
Study Director
Facility Information:
Facility Name
HonorHealth-USOR HonorHealth ( Site 8000)
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85016
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
602-406-7730
Facility Name
Moores Cancer Center ( Site 0037)
City
La Jolla
State/Province
California
ZIP/Postal Code
92093-0698
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
858-822-6100
Facility Name
Kaiser Permanente Riverside Medical Center ( Site 0045)
City
Riverside
State/Province
California
ZIP/Postal Code
92505
Country
United States
Individual Site Status
Completed
Facility Name
Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0013)
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06511
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
203-688-4242
Facility Name
Mount Sinai Cancer Center ( Site 0018)
City
Miami Beach
State/Province
Florida
ZIP/Postal Code
33140
Country
United States
Individual Site Status
Completed
Facility Name
Sarasota Memorial Hospital ( Site 0005)
City
Sarasota
State/Province
Florida
ZIP/Postal Code
34239
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Northside Hospital ( Site 0017)
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30342
Country
United States
Individual Site Status
Completed
Facility Name
Southeastern Regional Medical Center ( Site 0046)
City
Newnan
State/Province
Georgia
ZIP/Postal Code
30265
Country
United States
Individual Site Status
Completed
Facility Name
Midwestern Regional Medical Center,Inc. DBA CTCA, Chicago ( Site 0003)
City
Zion
State/Province
Illinois
ZIP/Postal Code
60099
Country
United States
Individual Site Status
Completed
Facility Name
St. Vincent Hospital and Health Care Center, Inc ( Site 0006)
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46260
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Baptist Health Lexington ( Site 0042)
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40503
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
502-802-6829
Facility Name
Maryland Oncology Hematology, P.A.-USOR Maryland Oncology Hematology, P.A. ( Site 8002)
City
Rockville
State/Province
Maryland
ZIP/Postal Code
20850
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
301-933-3216
Facility Name
University of Massachusetts Medical School-Division of Gynecologic Oncology ( Site 0008)
City
Worcester
State/Province
Massachusetts
ZIP/Postal Code
01605
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
508-856-3216
Facility Name
Karmanos Cancer Institute ( Site 0029)
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Individual Site Status
Completed
Facility Name
St. Dominic's Hospital ( Site 0024)
City
Jackson
State/Province
Mississippi
ZIP/Postal Code
39216
Country
United States
Individual Site Status
Completed
Facility Name
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0026)
City
Hackensack
State/Province
New Jersey
ZIP/Postal Code
07601
Country
United States
Individual Site Status
Completed
Facility Name
The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0023)
City
New York
State/Province
New York
ZIP/Postal Code
10011
Country
United States
Individual Site Status
Completed
Facility Name
Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0016)
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
212-731-6455
Facility Name
Icahn School of Medicine at Mount Sinai ( Site 0052)
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Individual Site Status
Completed
Facility Name
Memorial Sloan Kettering Cancer Center ( Site 0009)
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
FirstHealth Clinical Trials ( Site 0050)
City
Pinehurst
State/Province
North Carolina
ZIP/Postal Code
28374
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
910-715-2200
Facility Name
Sanford Medical Center ( Site 0054)
City
Bismarck
State/Province
North Dakota
ZIP/Postal Code
58501
Country
United States
Individual Site Status
Completed
Facility Name
Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0055)
City
Fargo
State/Province
North Dakota
ZIP/Postal Code
58122
Country
United States
Individual Site Status
Completed
Facility Name
University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0039)
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
513-584-7698
Facility Name
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Providence Portland Medical Center ( Site 0031)
City
Portland
State/Province
Oregon
ZIP/Postal Code
97213
Country
United States
Individual Site Status
Completed
Facility Name
Sidney Kimmel Cancer Center - Jefferson Health ( Site 0053)
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
215-481-4000
Facility Name
University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0034)
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
AHN West Penn Hospital ( Site 0011)
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15224
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Asplundh Cancer Pavilion ( Site 0014)
City
Willow Grove
State/Province
Pennsylvania
ZIP/Postal Code
19090
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
215-481-4000
Facility Name
Sanford Cancer Center-Gynecologic Oncology ( Site 0002)
City
Sioux Falls
State/Province
South Dakota
ZIP/Postal Code
57104
Country
United States
Individual Site Status
Completed
Facility Name
Texas Oncology - Austin-USOR Texas Oncology - Austin ( Site 8003)
City
Austin
State/Province
Texas
ZIP/Postal Code
78731
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
512-421-4250
Facility Name
Texas Oncology - Dallas-USOR Texas Oncology - Dallas (Sammons) ( Site 8005)
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
214-370-1000
Facility Name
Lyndon B. Johnson General Hospital ( Site 0056)
City
Houston
State/Province
Texas
ZIP/Postal Code
77026
Country
United States
Individual Site Status
Completed
Facility Name
University of Texas MD Anderson Cancer Center ( Site 0040)
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Completed
Facility Name
Texas Oncology - Tyler-USOR Texas Oncology - Northeast Texas ( Site 8004)
City
Tyler
State/Province
Texas
ZIP/Postal Code
75702
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
903-579-9800
Facility Name
VCU Health Adult Outpatient Pavillion ( Site 0022)
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23219
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
804-828-9080
Facility Name
Northern Cancer Institute ( Site 0206)
City
St Leonards
State/Province
New South Wales
ZIP/Postal Code
2065
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+61294631173
Facility Name
Westmead Hospital-Department of Gynaecological Oncology ( Site 0201)
City
Westmead
State/Province
New South Wales
ZIP/Postal Code
2145
Country
Australia
Individual Site Status
Completed
Facility Name
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si
City
Brisbane
State/Province
Queensland
ZIP/Postal Code
4029
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+61736467983
Facility Name
Monash Health ( Site 0202)
City
Clayton
State/Province
Victoria
ZIP/Postal Code
3168
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+61 3 8572 2936
Facility Name
Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0207)
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3000
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
61396561697
Facility Name
Epworth Freemasons ( Site 0203)
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3002
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+61399368043
Facility Name
St. John of God Subiaco Hospital-Oncology Clinical Trials Unit ( Site 0204)
City
Subiaco
State/Province
Western Australia
ZIP/Postal Code
6008
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+61864659204
Facility Name
Institut Jules Bordet-Medicine Oncology ( Site 0321)
City
Bruxelles
State/Province
Bruxelles-Capitale, Region De
ZIP/Postal Code
1000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+3225413142
Facility Name
Grand Hôpital de Charleroi-Oncology & Hematology ( Site 0323)
City
Charleroi
State/Province
Hainaut
ZIP/Postal Code
6000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+3271104766
Facility Name
Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman ( Site 0320)
City
Liège
State/Province
Liege
ZIP/Postal Code
4000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+3242844454
Facility Name
Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 3005)
City
Natal
State/Province
Rio Grande Do Norte
ZIP/Postal Code
59075-740
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
5584991425228
Facility Name
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 3001)
City
São Paulo
State/Province
Sao Paulo
ZIP/Postal Code
01246-000
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
5511994070479
Facility Name
A. C. Camargo Cancer Center-CAPEC ( Site 3003)
City
Sao Paulo
ZIP/Postal Code
01509-010
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
1121895000
Facility Name
Cross Cancer Institute ( Site 0513)
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 1Z2
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
780-432-8762
Facility Name
BC Cancer Kelowna ( Site 0517)
City
Kelowna
State/Province
British Columbia
ZIP/Postal Code
V1Y 5L3
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
12507123996
Facility Name
BC Cancer Vancouver-Clinical Trials Unit ( Site 0518)
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V5Z 4E6
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
6048776000
Facility Name
Sunnybrook Health Sciences - Odette Cancer Centre ( Site 0509)
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4N 3M5
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
416-480-5000 x89828
Facility Name
Princess Margaret Cancer Centre ( Site 0510)
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2M9
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
416-946-4501 x 3911
Facility Name
Jewish General Hospital ( Site 0504)
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3T 1E2
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
5143408222ext23114
Facility Name
Centre Hospitalier de l'Université de Montréal ( Site 0519)
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H2X 3E4
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
514-890-8000 x30777
Facility Name
McGill University Health Centre ( Site 0505)
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H4A 3J1
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
514-934-1934 ext. 31975
Facility Name
Saskatoon Cancer Center-Clinical Research Department ( Site 0520)
City
Saskatoon
State/Province
Saskatchewan
ZIP/Postal Code
S7N4H4
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
(306) 655-2691
Facility Name
FALP-UIDO ( Site 0602)
City
Santiago
State/Province
Region M. De Santiago
ZIP/Postal Code
7500921
Country
Chile
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
96792467
Facility Name
Pontificia Universidad Catolica de Chile-Centro del Cáncer ( Site 0604)
City
Santiago
State/Province
Region M. De Santiago
ZIP/Postal Code
8330032
Country
Chile
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
56223547919
Facility Name
Bradfordhill-Clinical Area ( Site 0603)
City
Santiago
State/Province
Region M. De Santiago
ZIP/Postal Code
8420383
Country
Chile
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+56978878489
Facility Name
Anhui Provincial Hospital-Obstetrics and Gynecology ( Site 0730)
City
Hefei
State/Province
Anhui
ZIP/Postal Code
230001
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+8618651642198
Facility Name
Beijing Obstetric and Gynecology Hospital ( Site 0740)
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100026
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+8613810018514
Facility Name
Peking University First Hospital ( Site 0723)
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100034
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
13701353184
Facility Name
Beijing Cancer hospital ( Site 0715)
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100142
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
13641356816
Facility Name
2nd Affiliated Hospital Chongqing Medical Universi ( Site 0745)
City
Chongqing
State/Province
Chongqing
ZIP/Postal Code
400000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
023 62887460
Facility Name
Southwest Hospital of Third Military Medical University ( Site 0719)
City
Chongqing
State/Province
Chongqing
ZIP/Postal Code
400038
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
023-68766775
Facility Name
Fuling Central Hospital ( Site 0733)
City
Fulingqu
State/Province
Chongqing
ZIP/Postal Code
408000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
023-7211 5908
Facility Name
Fujian Provincial Cancer Hospital ( Site 0720)
City
Fuzhou
State/Province
Fujian
ZIP/Postal Code
350014
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+86 0591-62752500
Facility Name
SUN YAT-SEN UNIVERSITY CANCER CENTRE ( Site 0710)
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510060
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
02087343102
Facility Name
Cancer Hospital of Shantou University Medical College ( Site 0732)
City
Shantou
State/Province
Guangdong
ZIP/Postal Code
515041
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
075488573563
Facility Name
Affiliated Hospital of Guangdong Medical College ( Site 0731)
City
Zhanjiang
State/Province
Guangdong
ZIP/Postal Code
524004
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
07592369367
Facility Name
Guangxi Medical University Affiliated Tumor Hospital-Gynecological oncology ( Site 0704)
City
Nanning
State/Province
Guangxi
ZIP/Postal Code
530021
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+8615278015900
Facility Name
Hainan General Hospital ( Site 0703)
City
Haikou
State/Province
Hainan
ZIP/Postal Code
570311
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+8613876082272
Facility Name
Harbin Medical University Cancer Hospital ( Site 0711)
City
Harbin
State/Province
Heilongjiang
ZIP/Postal Code
150081
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
13306304488
Facility Name
Henan Cancer Hospital ( Site 0713)
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450008
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
13837196622
Facility Name
Wuhan Union Hospital-Medical Oncology ( Site 0716)
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430022
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
13307187507
Facility Name
Xiangya Hospital Central South University-Gynecology ( Site 0708)
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410008
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+8615116296585
Facility Name
Hunan Cancer Hospital ( Site 0709)
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410013
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
0731-88651669
Facility Name
Jiangsu Province Hospital-Oncology Department ( Site 0707)
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210003
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
025-68306259
Facility Name
The First Affiliated Hospital of Nanchang University ( Site 0729)
City
Nanchang
State/Province
Jiangxi
ZIP/Postal Code
330006
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
8613767181058
Facility Name
The First Hospital of Jilin University ( Site 0705)
City
Changchun
State/Province
Jilin
ZIP/Postal Code
130021
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
8613500825736
Facility Name
Shaanxi Provincial Cancer Hospital ( Site 0714)
City
XI An
State/Province
Shaanxi
ZIP/Postal Code
710061
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
13772051815
Facility Name
Binzhou Medical University Hospital-Oncology department ( Site 0735)
City
Binzhou
State/Province
Shandong
ZIP/Postal Code
256603
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
15254311599
Facility Name
Obstetrics & Gynecology Hospital of Fudan University ( Site 0702)
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200011
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
021-63453967
Facility Name
Shanghai First Maternity and Infant Hospital-Gynecology department ( Site 0717)
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
201204
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
021-20261234
Facility Name
West China Second University Hospital Sichuan University ( Site 0701)
City
Chengdu
State/Province
Sichuan
ZIP/Postal Code
610066
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+8618180609015
Facility Name
Tianjin Medical University Cancer Institute and Hospital ( Site 0706)
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300060
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
022-23343120
Facility Name
Yunnan Province Cancer Hospital-Gynecology Department ( Site 0721)
City
Kunming
State/Province
Yunnan
ZIP/Postal Code
650118
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+8613888087358
Facility Name
The Affiliated Women's Hospital of Zhejiang University-Obstetrics and Gynecology ( Site 0726)
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310006
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
0571-89992206
Facility Name
Zhejiang Cancer Hospital-Oncology ( Site 0700)
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310022
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
0571-88122482
Facility Name
The First Affiliated Hospital of Wenzhou Medical University-Gynecology ( Site 0725)
City
Wenzhou
State/Province
Zhejiang
ZIP/Postal Code
325000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
13806696807
Facility Name
Fakultní nemocnice Brno Bohunice-Gynekologicko-porodnicka klinika ( Site 0404)
City
Brno
State/Province
Brno-mesto
ZIP/Postal Code
62500
Country
Czechia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+420532233843
Facility Name
Fakultni nemocnice Ostrava-Gynekologicko-porodnicka klinika ( Site 0403)
City
Ostrava
State/Province
Moravskoslezsky Kraj
ZIP/Postal Code
708 52
Country
Czechia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+420597371825
Facility Name
Nemocnice AGEL Novy Jicin a.s.-Oddeleni radioterapie a onkologie ( Site 0406)
City
Nový Jiín
State/Province
Novy Jicin
ZIP/Postal Code
741 01
Country
Czechia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+420556416127
Facility Name
Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 0402)
City
Olomouc
State/Province
Olomoucky Kraj
ZIP/Postal Code
779 00
Country
Czechia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+420588444288
Facility Name
Vseobecna fakultni nemocnice v Praze-Gynekologicko-porodnicka klinika 1.LF a VFN ( Site 0405)
City
Praha
State/Province
Praha 2
ZIP/Postal Code
12808
Country
Czechia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+420224967451
Facility Name
Fakultni nemocnice Bulovka-Gynekologicko-porodnicka klinika ( Site 0401)
City
Praha
State/Province
Praha 8
ZIP/Postal Code
180 00
Country
Czechia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+420266083202
Facility Name
Nemocnice Tomase Bati ve Zline-Onkologické oddělení ( Site 0407)
City
Zlín
State/Province
Zlinsky Kraj
ZIP/Postal Code
762 75
Country
Czechia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+420577552344
Facility Name
Fakultni nemocnice Kralovske Vinohrady-Gynekologicko-porodnická klinika ( Site 0408)
City
Praha 10
ZIP/Postal Code
10034
Country
Czechia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
00420602574306
Facility Name
Rigshospitalet ( Site 0903)
City
Copenhagen
State/Province
Hovedstaden
ZIP/Postal Code
2100
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
35453545
Facility Name
Herlev and Gentofte Hospital ( Site 0902)
City
Copenhagen
State/Province
Hovedstaden
ZIP/Postal Code
2730
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
38683868
Facility Name
Aalborg Universitetshospital, Syd ( Site 0905)
City
Aalborg
State/Province
Nordjylland
ZIP/Postal Code
9000
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
4597660000
Facility Name
Roskilde Sygehus-Oncology department ( Site 0904)
City
Roskilde
State/Province
Sjaelland
ZIP/Postal Code
DK-4000
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
46323200
Facility Name
Tampereen yliopistollinen sairaala-Gynecology and Obstetrics ( Site 1001)
City
Tampere
State/Province
Pirkanmaa
ZIP/Postal Code
33520
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
358408484029
Facility Name
Kuopion Yliopistollinen Sairaala ( Site 1002)
City
Kuopio
State/Province
Pohjois-Savo
ZIP/Postal Code
70210
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
358447174617
Facility Name
Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus) ( Site 1003)
City
Helsinki
State/Province
Uusimaa
ZIP/Postal Code
00290
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
358504286945
Facility Name
Universitaetsklinikum Ulm ( Site 1106)
City
Ulm
State/Province
Baden-Wurttemberg
ZIP/Postal Code
89081
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+4973150058521
Facility Name
Universitätsklinikum Bonn-Gynaecological oncology ( Site 1105)
City
Bonn
State/Province
Nordrhein-Westfalen
ZIP/Postal Code
53127
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+4915158280471
Facility Name
Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Frauenheilkunde und Gebur
City
Dresden
State/Province
Sachsen
ZIP/Postal Code
01307
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+493514584202
Facility Name
Charité Campus Virchow-Klinikum ( Site 1103)
City
Berlin
ZIP/Postal Code
13353
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+4930450564404
Facility Name
Országos Onkológiai Intézet-Ngyógyászat ( Site 1201)
City
Budapest
ZIP/Postal Code
1122
Country
Hungary
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+3612248600
Facility Name
Bon Secours Cork Hospital ( Site 1305)
City
Cork
ZIP/Postal Code
T12 DV56
Country
Ireland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+353 021 4542807
Facility Name
St. James's Hospital-Cancer clinical trials office ( Site 1301)
City
Dublin
ZIP/Postal Code
D08 E9P6
Country
Ireland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+353 (01) 410 3000
Facility Name
Soroka Medical Center ( Site 1403)
City
Be'er Sheva
ZIP/Postal Code
8410101
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+97286244068
Facility Name
Rambam Health Care Campus-Gyneco-oncology unit ( Site 1402)
City
Haifa
ZIP/Postal Code
3109601
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+97247773872
Facility Name
Edith Wolfson Medical Center-Obstetrics & Gynecology ( Site 1405)
City
Holon
ZIP/Postal Code
5822012
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+97235028795
Facility Name
Shaare Zedek Medical Center ( Site 1404)
City
Jerusalem
ZIP/Postal Code
9103102
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+97226555727
Facility Name
Sheba Medical Center ( Site 1401)
City
Ramat Gan
ZIP/Postal Code
5265601
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+97235303157
Facility Name
Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Oncologia Sperimentale Uro-Genitale ( Site 1
City
Napoli
State/Province
Campania
ZIP/Postal Code
80131
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+390815903637
Facility Name
IRCCS - AOU di Bologna-SSD Oncologia medica Addarii ( Site 1503)
City
Bologna
State/Province
Emilia-Romagna
ZIP/Postal Code
40138
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+39 0512144548
Facility Name
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-Oncologia Medica ( Site 1513)
City
Meldola
State/Province
Emilia-Romagna
ZIP/Postal Code
47014
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
390543739100
Facility Name
Fondazione Policlinico Universitario Agostino Gemelli-Ginecologia Oncologica ( Site 1502)
City
Roma
State/Province
Lazio
ZIP/Postal Code
oo168
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+390630158545
Facility Name
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Chirurgia Ginecologica ( Site 150
City
Milan
State/Province
Lombardia
ZIP/Postal Code
20133
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+39 02 23902719
Facility Name
Ospedale Mauriziano-SCDU ONCOLOGIA MEDICA ( Site 1514)
City
Torino
State/Province
Piemonte
ZIP/Postal Code
10128
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
00390115085394
Facility Name
Istituto Nazionale Tumori Regina Elena-Oncologia Medica 1 ( Site 1504)
City
Rome
State/Province
Roma
ZIP/Postal Code
00144
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
390652666771
Facility Name
Azienda Ospedaliera Universitaria Careggi-SOD ONCOLOGIA MEDICA ( Site 1509)
City
Firenze
State/Province
Toscana
ZIP/Postal Code
50134
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+390557947298
Facility Name
AULSS8 Berica-Ospedale S.Bortolo-ONCOLOGIA CLINICA ( Site 1510)
City
Vicenza
State/Province
Veneto
ZIP/Postal Code
36100
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
00390444753906
Facility Name
Istituto Europeo di Oncologia IRCCS-Divisione di Ginecologia Oncologica ( Site 1506)
City
Milano
ZIP/Postal Code
20141
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+39 02 57489543
Facility Name
National Cancer Center Hospital East ( Site 1604)
City
Kashiwa
State/Province
Chiba
ZIP/Postal Code
277-8577
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+81-19-613-7111
Facility Name
National Hospital Organization Shikoku Cancer Center ( Site 1611)
City
Matsuyama
State/Province
Ehime
ZIP/Postal Code
791-0280
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+81-89-999-1111
Facility Name
Ehime University Hospital ( Site 1614)
City
Toon
State/Province
Ehime
ZIP/Postal Code
791-0295
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+81-89-964-5111
Facility Name
Kurume University Hospital ( Site 1612)
City
Kurume
State/Province
Fukuoka
ZIP/Postal Code
830-0011
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+81-942-35-3311
Facility Name
Gunma Prefectural Cancer Center-Gynecology ( Site 1603)
City
Ota
State/Province
Gunma
ZIP/Postal Code
373-8550
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+81-276-38-0771
Facility Name
Hokkaido University Hospital ( Site 1601)
City
Sapporo
State/Province
Hokkaido
ZIP/Postal Code
060-8648
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+81-11-716-1161
Facility Name
Tsukuba University Hospital ( Site 1618)
City
Tsukuba
State/Province
Ibaraki
ZIP/Postal Code
305-8576
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+81-29-853-3049
Facility Name
Iwate Medical University Hospital ( Site 1602)
City
Shiwa-gun Yahaba-cho
State/Province
Iwate
ZIP/Postal Code
028-3695
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+81-19-613-7111
Facility Name
Niigata University Medical & Dental Hospital ( Site 1613)
City
Chuo-ku, Niigata
State/Province
Niigata
ZIP/Postal Code
951-8520
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+81-25-223-6161
Facility Name
Saitama Medical University International Medical Center ( Site 1605)
City
Hidaka-shi
State/Province
Saitama
ZIP/Postal Code
350-1200
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+81-42-984-4111
Facility Name
Shizuoka Cancer Center ( Site 1609)
City
Nagaizumi-cho,Sunto-gun
State/Province
Shizuoka
ZIP/Postal Code
411-8777
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+81-55-989-5222
Facility Name
National Cancer Center Hospital ( Site 1607)
City
Chuo-ku
State/Province
Tokyo
ZIP/Postal Code
104-0045
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+81-3-3542-2511
Facility Name
Japanese Foundation for Cancer Research ( Site 1616)
City
Koto
State/Province
Tokyo
ZIP/Postal Code
135-8550
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+81-3-3520-0111
Facility Name
The Jikei University Hospital ( Site 1615)
City
Minato-ku
State/Province
Tokyo
ZIP/Postal Code
105-8471
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+81-3-3433-1111
Facility Name
Keio university hospital ( Site 1606)
City
Shinjyuku-ku
State/Province
Tokyo
ZIP/Postal Code
160-8582
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+81-3-3353-1211
Facility Name
National Hospital Organization Kyushu Cancer Center ( Site 1608)
City
Fukuoka
ZIP/Postal Code
811-1395
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+81-92-541-3231
Facility Name
Osaka International Cancer Institute ( Site 1617)
City
Osaka
ZIP/Postal Code
541-8567
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
81669451181
Facility Name
Seoul National University Hospital ( Site 2302)
City
Seoul
ZIP/Postal Code
03080
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+82220723511
Facility Name
Severance Hospital, Yonsei University Health System-Gynecologic cancer center ( Site 2301)
City
Seoul
ZIP/Postal Code
03722
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+82222282760
Facility Name
Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology ( Site 2303)
City
Seoul
ZIP/Postal Code
05505
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+82230103640
Facility Name
Gangnam Severance Hospital ( Site 2304)
City
Seoul
ZIP/Postal Code
06273
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+82220193430
Facility Name
Radboudumc-Medical Oncology ( Site 1703)
City
Nijmegen
State/Province
Gelderland
ZIP/Postal Code
6525 GA
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+31243667251
Facility Name
Maastricht UMC+ ( Site 1709)
City
Maastricht
State/Province
Limburg
ZIP/Postal Code
6229 HX
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+31433876007
Facility Name
Catharina Ziekenhuis-Oncology ( Site 1704)
City
Eindhoven
State/Province
Noord-Brabant
ZIP/Postal Code
5623 EJ
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+31402396622
Facility Name
Amsterdam UMC, locatie AMC ( Site 1706)
City
Amsterdam
State/Province
Noord-Holland
ZIP/Postal Code
1105 AZ
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+31205669111
Facility Name
Leids Universitair Medisch Centrum-Medical Oncology ( Site 1702)
City
Leiden
State/Province
Zuid-Holland
ZIP/Postal Code
2333 ZA
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+31715263464
Facility Name
Erasmus Medisch Centrum-Medical Oncology ( Site 1701)
City
Rotterdam
State/Province
Zuid-Holland
ZIP/Postal Code
3015 GD
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+31107034897
Facility Name
University Medical Center Groningen ( Site 1707)
City
Groningen
ZIP/Postal Code
9713 GZ
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+31503611847
Facility Name
Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 1705)
City
Utrecht
ZIP/Postal Code
3584 CX
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+31887556265
Facility Name
Auckland City Hospital-Cancer & Blood Research ( Site 1801)
City
Auckland
ZIP/Postal Code
1023
Country
New Zealand
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+64211561492
Facility Name
Oslo universitetssykehus, Radiumhospitalet ( Site 1901)
City
Oslo
ZIP/Postal Code
0379
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+4748512384
Facility Name
Centrum Onkologii Ziemi Lubelskiej ( Site 2006)
City
Lublin
State/Province
Lubelskie
ZIP/Postal Code
20-090
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
0048603866462
Facility Name
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 2007)
City
Siedlce
State/Province
Mazowieckie
ZIP/Postal Code
08-110
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
0048256403485
Facility Name
Szpital Kliniczny im. Księżnej Anny Mazowieckiej ( Site 2009)
City
Warsaw
State/Province
Mazowieckie
ZIP/Postal Code
00-315
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+48225966512
Facility Name
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Ginekologii Onkologicznej ( Sit
City
Warszawa
State/Province
Mazowieckie
ZIP/Postal Code
02-781
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+48225462295
Facility Name
Bialostockie Centrum Onkologii-Oddzial Onkologii Ginekologicznej ( Site 2003)
City
Bialystok
State/Province
Podlaskie
ZIP/Postal Code
15-027
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
0048856646728
Facility Name
Narodowy Instytut Onkologii - Oddzial w Gliwicach-III Klinika Radioterapii i Chemioterapii ( Site 20
City
Gliwice
State/Province
Slaskie
ZIP/Postal Code
44-101
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+48322788613
Facility Name
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 2010)
City
Kielce
State/Province
Swietokrzyskie
ZIP/Postal Code
25-734
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+48413674128
Facility Name
Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Me-Oddzial Ginekologii Onkologicznej ( Sit
City
Poznan
State/Province
Wielkopolskie
ZIP/Postal Code
61-848
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+48501149213
Facility Name
Moscow City Oncology Hospital #62 ( Site 2204)
City
Krasnogorsk
State/Province
Moskovskaya Oblast
ZIP/Postal Code
143423
Country
Russian Federation
Individual Site Status
Suspended
Facility Name
Yaroslavl Regional Cancer Hospital-Oncology ( Site 2202)
City
Yaroslavl
State/Province
Yaroslavskaya Oblast
ZIP/Postal Code
150054
Country
Russian Federation
Individual Site Status
Suspended
Facility Name
Institut Català d'Oncologia - L'Hospitalet-Medical Oncology ( Site 2406)
City
Hospitalet
State/Province
Barcelona
ZIP/Postal Code
08907
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+34932607333
Facility Name
CHUAC-Complejo Hospitalario Universitario A Coruña ( Site 2405)
City
A Coruña
State/Province
La Coruna
ZIP/Postal Code
15006
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
0034981178000
Facility Name
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 2402)
City
Madrid
State/Province
Madrid, Comunidad De
ZIP/Postal Code
28034
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+34913368263
Facility Name
COMPLEJO HOSPITALARIO DE NAVARRA ( Site 2407)
City
Pamplona
State/Province
Navarra
ZIP/Postal Code
31009
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+34 848422576
Facility Name
Fundación Instituto Valenciano de Oncología-Oncologico ( Site 2404)
City
Valencia
State/Province
Valenciana, Comunitat
ZIP/Postal Code
46009
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+34961114013
Facility Name
Hospital Universitari Vall d'Hebron ( Site 2403)
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+34934892658
Facility Name
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 2401)
City
Sevilla
ZIP/Postal Code
41013
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+34955013068
Facility Name
Skånes Universitetssjukhus Lund-Department of Hematology ( Site 2504)
City
Lund
State/Province
Skane Lan
ZIP/Postal Code
22185
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+46 46 17 10 00
Facility Name
Karolinska Universitetssjukhuset Solna ( Site 2502)
City
Solna
State/Province
Stockholms Lan
ZIP/Postal Code
171 64
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+46 851770000
Facility Name
Norrlands universitetssjukhus-Cancercentrum ( Site 2503)
City
Umeå
State/Province
Vasterbottens Lan
ZIP/Postal Code
901 85
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+46 907850000
Facility Name
Taichung Veterans General Hospital ( Site 2602)
City
Taichung
ZIP/Postal Code
407
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
886-4-23592525 ext 5822
Facility Name
NATIONAL CHENG-KUNG UNI. HOSP. ( Site 2604)
City
Tainan
ZIP/Postal Code
704
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
886-6-2353535 ext 5222
Facility Name
National Taiwan University Hospital ( Site 2603)
City
Taipei
ZIP/Postal Code
100
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
886-2-23123456 ext 71964
Facility Name
Mackay Memorial Hospital ( Site 2601)
City
Taipei
ZIP/Postal Code
10449
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+886-2-25433535
Facility Name
Taipei Veterans General Hospital ( Site 2605)
City
Taipei
ZIP/Postal Code
11217
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+886-2-28712121
Facility Name
Istanbul Universitesi Cerrahpasa ( Site 2702)
City
Fatih
State/Province
Istanbul
ZIP/Postal Code
34098
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+902124143525
Facility Name
Hacettepe Universite Hastaneleri-oncology hospital ( Site 2704)
City
Ankara
ZIP/Postal Code
06230
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
905065090160
Facility Name
Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 2706)
City
Ankara
ZIP/Postal Code
06800
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
905555306271
Facility Name
Akdeniz Universitesi Hastanesi ( Site 2701)
City
Antalya
ZIP/Postal Code
07070
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
905052312377
Facility Name
Istanbul University Capa Campus-department of obstetrics and gynaecology ( Site 2705)
City
Istanbul
ZIP/Postal Code
34093
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
905056309763
Facility Name
T.C. Saglik Bakanligi Turkiye Kamu Hastaneleri Kurumu - Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma
City
Istanbul
ZIP/Postal Code
34440
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+902124147171
Facility Name
St Bartholomew's Hospital ( Site 2804)
City
London
State/Province
England
ZIP/Postal Code
EC1A 7BE
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+44 0203 416 5000
Facility Name
The Christie ( Site 2807)
City
Manchester
State/Province
England
ZIP/Postal Code
M20 4BX
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+44161446 8217
Facility Name
The Beatson West of Scotland Cancer Centre ( Site 2805)
City
Glasgow
State/Province
Glasgow City
ZIP/Postal Code
G12 0YN
Country
United Kingdom
Individual Site Status
Completed
Facility Name
ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 2806)
City
London
State/Province
London, City Of
ZIP/Postal Code
SW3 6JJ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+44 20 7352 8171
Facility Name
Hammersmith Hospital-Medical Oncology ( Site 2808)
City
London
State/Province
London, City Of
ZIP/Postal Code
W12 0HS
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+44 20 3312 6614
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
IPD Sharing URL
http://engagezone.msd.com/ds_documentation.php
Links:
URL
https://www.merckclinicaltrials.com/
Description
Merck Clinical Trial Information
Learn more about this trial
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
We'll reach out to this number within 24 hrs